AstraZeneca Plc has begun a large-scale human trial of its coronavirus vaccine in the U.S. following a brief delay, according to researchers from the University of Wisconsin School of Medicine and Public Health who are helping conduct the tests.
The university, one of the sites for the 30,000 person trial, plans to begin injecting healthy volunteers on Tuesday, according to William Hartman, a UW Health anesthesiologist and investigator on the trial. It plans to ramp up to injecting 50 people a day shortly after the Sept. 7 Labor Day holiday, he said in an interview.
AstraZeneca didn’t immediately respond to a request for comment.
The AstraZeneca shot, invented by researchers at the University of Oxford, is one of the farthest along of numerous Covid-19 vaccines in development. In addition to the U.S. trial, a final-stage test of the inoculation is underway in the U.K. and could yield preliminary results as soon as next month. Other companies that have Covid-19 vaccines in phase 3 trials include Moderna Inc. and Pfizer Inc.
78,512 in IndiaMost new cases today
+2% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-0.9933 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23
5.4% Global GDP Tracker (annualized), July